The Application Value of Spectral CT in the Accurate Staging of Breast Cancer
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 150
- Primary Endpoint
- Pathological TNM staging
Study Overview
Brief Summary
Spectral CT was used to prospectively collect medical images and clinical data related to breast cancer, evaluate the effect of image quality in the diagnosis of breast cancer, and evaluate the application value in the accurate staging of breast cancer, so as to provide a more accurate clinical basis for diagnosis, promote the development of individualized treatment, and ultimately improve the prognosis of patients.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Diagnostic
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 80 Years (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •(a) Chest quark energy spectrum CT examination was performed within 1 week before treatment
- •(b) Age ≥ 18
- •(c) Suspected breast cancer patients
- •(d) Patients who signed informed consent
Exclusion Criteria
- •(a) Severe cardiac, pulmonary and renal insufficiency
- •(b) Allergic to iodine contrast media
- •(c) Unable to cooperate to complete CT examination
- •(d) Quark spectrum CT image is poor and cannot be used
- •(e) Male, pregnant and lactating female
- •(f) Combined with other tumor history
- •(g) Incomplete clinical and pathological data
- •(h) Pathologically confirmed non breast cancer
Arms & Interventions
The application value of spectral CT in the accurate staging of breast cancer
Prospectively collect medical images and clinical data related to breast cancer using Philips Quark CT equipment, and evaluate the diagnostic accuracy and clinical application value in the accurate staging of breast cancer. Patients diagnosed with breast cancer in Yunnan Provincial Cancer Hospital from April 2025 to May 2026 were consecutively included, and after scanning with Philips Quark CT, the TNM stage of breast cancer patients was assessed by two radiologists, and finally statistical analysis was performed.
Intervention: To explore the value of spectral CT in the diagnosis and treatment of breast cancer (Diagnostic Test)
Outcomes
Primary Outcomes
Pathological TNM staging
Time Frame: 1 day
Pathological examination information: The pathology results using surgery/biopsy data are the gold standard, and the depth of tumor invasion, lymph node metastasis, and distant metastasis are recorded
Secondary Outcomes
No secondary outcomes reported